Herantis Pharma Oyj

HRTIS

FI4000087861

Biotechnology & Medical Research

Market Closed - Nasdaq Helsinki Other stock markets 11:23:44 2024-04-19 am EDT			5-day change	1st Jan Change
1.435 ^EUR	-1.03%		+2.50%	-8.89%

Mar. 06	Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024

Herantis Pharma Oyj: Managers' Transactions - Antti Vuolanto

September 21, 2022 at 10:01 am EDT

Herantis Pharma Plc

Company release 21 September 2022 at 5:00pm EEST

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Antti Vuolanto

Position: Chief Executive Officer

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 19874/5/4

____________________________________________

Transaction date: 2022-09-21

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Instrument name: 2022 option rights in Herantis Pharma Plc

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 50000 Unit price: 0 EUR

Aggregated transactions

(1): Volume: 50000 Volume weighted average price: 0 EUR

____________________________________________

Further information:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

Distribution:

Main media
www.herantis.com

https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-oyj--managers--transactions---antti-vuolanto,c3634473

https://mb.cision.com/Main/18884/3634473/1629319.pdf

Latest news about Herantis Pharma Oyj

Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024	Mar. 06
Transcript : Herantis Pharma Oyj - Special Call	23-10-25
Herantis Pharma's Early-stage Study of Parkinson's Therapy Shows Positive Data; Stock Surges	23-10-25	MT
Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096	23-10-25	CI
Herantis Pharma Secures EUR4.5 Million Loan Waive-off From Business Finland	23-09-25	MT
Transcript : Herantis Pharma Oyj, H1 2023 Earnings Call, Aug 24, 2023	23-08-24
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study	23-08-22	CI
Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096	23-07-04	CI
Herantis Pharma Doses First Patient in Phase 1 Trial for Parkinson's Disease Therapy	23-04-19	MT
Herantis Pharma Oyj Announces First Healthy Volunteer Dosed in the Phase 1a Clinical Study for the Parkinson's Disease Drug Candidate, HER-096	23-04-19	CI
Transcript : Herantis Pharma Oyj, H2 2022 Earnings Call, Mar 02, 2023	23-03-02
Herantis Pharma Shares Surge on Approval of Clinical Trial Application For Parkison's Disease Treatment	23-02-20	MT
Herantis Pharma plc Announces Approval of Clinical Trial Application for A Phase 1 Study for HER-096	23-02-20	CI
Transcript : Herantis Pharma Oyj - Special Call	23-01-19
Herantis Pharma Oyj Announces Submission of A Clinical Trial Application for A Phase 1 Study for HER-096	22-12-19	CI
Herantis Pharma Secures Nasdaq Stockholm's Approval for Delisting	22-12-05	MT
Finland's Herantis Pharma Applies to Cancel Secondary Listing on Nasdaq First North Growth Market Sweden	22-12-01	MT
Herantis Pharma plc Announces Appointments to Shareholders' Nomination Committee	22-10-26	CI
Transcript : Herantis Pharma Oyj, H1 2022 Earnings Call, Aug 25, 2022	22-08-25
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Herantis Pharma plc Announces Executive Changes	22-07-08	CI
Herantis Pharma Says Trial Results Support Development of Neurodegenerative Diseases Treatment	22-04-28	MT
Herantis Pharma Oyj Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs	22-04-28	CI

Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinsonâs disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-04-22 - Alzheimers & Parkinsons Drug Development Summit

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HERANTIS PHARMA OYJ	-8.89%	31.17M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs